Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

• Status: Completed
• Trial end date: 2016-02-29
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Edison Pharmaceuticals Inc; PTC Therapeutics
• Treatments: Ubiquinone

Criteria

Inclusion Criteria:

1. Diagnosis of genetically confirmed Friedreich's ataxia

2. Visual acuity at baseline more than 15 letters on EDTRS at four meters

3. FARS score of 20 to 90

4. Agreement to use contraception if within reproductive years (see specifics in section D1, page 21)

5. Hormone replacement therapy, if used, must remain stable for the duration of the study

6. Willingness and ability to comply with study procedures

7. Willingness and ability to arrive at study site day prior to evaluations

8. Abstention from use of dietary supplements and non-prescribed medications at least 30 days prior to initiation of treatment and for the duration of the study. This would specifically include idebenone, Coenzyme Q10 and vitamin E

9. Abstention from use of other investigative or non-approved drugs within 30 days of enrollment and for the duration of the study

Exclusion Criteria:

1. Allergy to EPI-743 or sesame oil or nuts

2. Clinically significant bleeding condition or abnormal PT/PTT INR (INR > two; PTT > two-times normal)

3. Liver insufficiency with LFTs greater than three-times upper normal limit at screening

4. Renal insufficiency with creatinine > 1.5 at screening

5. Fat malabsorption syndromes

6. Any other respiratory chain diseases of the mitochondria or inborn errors of metabolism

7. Any other ophthalmologic conditions

8. History of alcohol or drug abuse

9. Clinically significant cardiomyopathy with ejection fraction < 40 percent at screening

10. Clinically significant arrhythmia within past two years requiring treatment

11. Anticoagulant therapy within 30 days of enrollment.